Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 1 to 20 of 82

1.

Capillary morphogenesis gene 2 inhibits growth of breast cancer cells and is inversely correlated with the disease progression and prognosis.

Ye L, Sun PH, Malik MF, Mason MD, Jiang WG.

J Cancer Res Clin Oncol. 2014 Mar 26. [Epub ahead of print]

PMID:
24667935
[PubMed - as supplied by publisher]
2.

Enhancement of T Cell Responses as a Result of Synergy between Lower Doses of Radiation and T Cell Stimulation.

Spary LK, Al-Taei S, Salimu J, Cook AD, Ager A, Watson HA, Clayton A, Staffurth J, Mason MD, Tabi Z.

J Immunol. 2014 Apr 1;192(7):3101-10. doi: 10.4049/jimmunol.1302736. Epub 2014 Mar 5.

PMID:
24600032
[PubMed - in process]
3.

Proteomics Analysis of Cancer Exosomes Using a Novel Modified Aptamer-based Array (SOMAscanTM) Platform.

Webber J, Stone TC, Katilius E, Smith BC, Gordon B, Mason MD, Tabi Z, Brewis IA, Clayton A.

Mol Cell Proteomics. 2014 Apr;13(4):1050-64. doi: 10.1074/mcp.M113.032136. Epub 2014 Feb 6.

PMID:
24505114
[PubMed - in process]
Free PMC Article
4.

Prostate transglutaminase (TGase-4, TGaseP) enhances the adhesion of prostate cancer cells to extracellular matrix, the potential role of TGase-core domain.

Jiang WG, Ye L, Sanders AJ, Ruge F, Kynaston HG, Ablin RJ, Mason MD.

J Transl Med. 2013 Oct 25;11:269. doi: 10.1186/1479-5876-11-269.

PMID:
24161123
[PubMed - in process]
Free PMC Article
5.

Receptor-like protein tyrosine phosphatase κ negatively regulates the apoptosis of prostate cancer cells via the JNK pathway.

Sun PH, Ye L, Mason MD, Jiang WG.

Int J Oncol. 2013 Nov;43(5):1560-8. doi: 10.3892/ijo.2013.2082. Epub 2013 Aug 29.

PMID:
24002526
[PubMed - in process]
6.

The Kiss-1/Kiss-1R complex as a negative regulator of cell motility and cancer metastasis (Review).

Ji K, Ye L, Mason MD, Jiang WG.

Int J Mol Med. 2013 Oct;32(4):747-54. doi: 10.3892/ijmm.2013.1472. Epub 2013 Aug 21. Review.

PMID:
23969598
[PubMed - indexed for MEDLINE]
7.

Antitumour effects of Yangzheng Xiaoji in human osteosarcoma: the pivotal role of focal adhesion kinase signalling.

Jiang WG, Ye L, Ji K, Ruge F, Wu Y, Gao Y, Ji J, Mason MD.

Oncol Rep. 2013 Sep;30(3):1405-13. doi: 10.3892/or.2013.2586. Epub 2013 Jul 3.

PMID:
23828123
[PubMed - in process]
8.

Prostate radiotherapy for men with metastatic disease: a new comparison in the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial.

Parker CC, Sydes MR, Mason MD, Clarke NW, Aebersold D, de Bono JS, Dearnaley DP, Ritchie AW, Russell JM, Thalmann G, Parmar MK, James ND.

BJU Int. 2013 May;111(5):697-9. doi: 10.1111/bju.12087. Review. No abstract available.

PMID:
23578233
[PubMed - indexed for MEDLINE]
9.

Protein tyrosine phosphatase kappa (PTPRK) is a negative regulator of adhesion and invasion of breast cancer cells, and associates with poor prognosis of breast cancer.

Sun PH, Ye L, Mason MD, Jiang WG.

J Cancer Res Clin Oncol. 2013 Jul;139(7):1129-39. doi: 10.1007/s00432-013-1421-5. Epub 2013 Apr 4.

PMID:
23552869
[PubMed - indexed for MEDLINE]
10.

Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.

Owen S, Ye L, Sanders AJ, Mason MD, Jiang WG.

Anticancer Res. 2013 Jan;33(1):199-206.

PMID:
23267146
[PubMed - indexed for MEDLINE]
11.

Matriptase-2 inhibits HECV motility and tubule formation in vitro and tumour angiogenesis in vivo.

Webb SL, Sanders AJ, Mason MD, Jiang WG.

Mol Cell Biochem. 2013 Mar;375(1-2):207-17. doi: 10.1007/s11010-012-1544-z. Epub 2012 Dec 13.

PMID:
23238872
[PubMed - indexed for MEDLINE]
12.

Protein tyrosine phosphatase µ (PTP µ or PTPRM), a negative regulator of proliferation and invasion of breast cancer cells, is associated with disease prognosis.

Sun PH, Ye L, Mason MD, Jiang WG.

PLoS One. 2012;7(11):e50183. doi: 10.1371/journal.pone.0050183. Epub 2012 Nov 20.

PMID:
23185569
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial.

Sydes MR, Parmar MK, Mason MD, Clarke NW, Amos C, Anderson J, de Bono J, Dearnaley DP, Dwyer J, Green C, Jovic G, Ritchie AW, Russell JM, Sanders K, Thalmann G, James ND.

Trials. 2012 Sep 15;13:168. doi: 10.1186/1745-6215-13-168.

PMID:
22978443
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Inhibitory effects of Yangzheng Xiaoji on angiogenesis and the role of the focal adhesion kinase pathway.

Jiang WG, Ye L, Ji K, Frewer N, Ji J, Mason MD.

Int J Oncol. 2012 Nov;41(5):1635-42. doi: 10.3892/ijo.2012.1627. Epub 2012 Sep 11.

PMID:
22971748
[PubMed - indexed for MEDLINE]
15.

The influence of matriptase-2 on prostate cancer in vitro: a possible role for β-catenin.

Webb SL, Sanders AJ, Mason MD, Jiang WG.

Oncol Rep. 2012 Oct;28(4):1491-7. doi: 10.3892/or.2012.1945. Epub 2012 Aug 2.

PMID:
22858929
[PubMed - indexed for MEDLINE]
16.

Psoriasin (S100A7) is a positive regulator of survival and invasion of prostate cancer cells.

Ye L, Sun PH, Martin TA, Sanders AJ, Mason MD, Jiang WG.

Urol Oncol. 2013 Nov;31(8):1576-83. doi: 10.1016/j.urolonc.2012.05.006. Epub 2012 Jun 12.

PMID:
22694938
[PubMed - in process]
17.

Psychological and immunological characteristics of fatigued women undergoing radiotherapy for early-stage breast cancer.

Courtier N, Gambling T, Enright S, Barrett-Lee P, Abraham J, Mason MD.

Support Care Cancer. 2013 Jan;21(1):173-81. doi: 10.1007/s00520-012-1508-6. Epub 2012 May 28.

PMID:
22644262
[PubMed - indexed for MEDLINE]
18.

Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma.

Al-Taei S, Salimu J, Lester JF, Linnane S, Goonewardena M, Harrop R, Mason MD, Tabi Z.

Lung Cancer. 2012 Aug;77(2):312-8. doi: 10.1016/j.lungcan.2012.03.008. Epub 2012 Apr 10.

PMID:
22498111
[PubMed - indexed for MEDLINE]
19.

Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.

James ND, Sydes MR, Mason MD, Clarke NW, Anderson J, Dearnaley DP, Dwyer J, Jovic G, Ritchie AW, Russell JM, Sanders K, Thalmann GN, Bertelli G, Birtle AJ, O'Sullivan JM, Protheroe A, Sheehan D, Srihari N, Parmar MK; STAMPEDE investigators.

Lancet Oncol. 2012 May;13(5):549-58. doi: 10.1016/S1470-2045(12)70088-8. Epub 2012 Mar 26. Erratum in: Lancet Oncol. 2013 Jan;14(1):e5.

PMID:
22452894
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.

Shelley MD, Jones G, Cleves A, Wilt TJ, Mason MD, Kynaston HG.

BJU Int. 2012 Feb;109(4):496-505. doi: 10.1111/j.1464-410X.2011.10880.x. Review.

PMID:
22313502
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk